The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 14, 2011
Filed:
May. 25, 2007
William R. Ewing, Yardley, PA (US);
Claudio Mapelli, Plainsboro, NJ (US);
Douglas James Riexinger, Flemington, NJ (US);
Ving G. Lee, Hamilton, NJ (US);
Richard B. Sulsky, West Trenton, NJ (US);
Yeheng Zhu, Stockton, NJ (US);
William R. Ewing, Yardley, PA (US);
Claudio Mapelli, Plainsboro, NJ (US);
Douglas James Riexinger, Flemington, NJ (US);
Ving G. Lee, Hamilton, NJ (US);
Richard B. Sulsky, West Trenton, NJ (US);
Yeheng Zhu, Stockton, NJ (US);
Bristol-Myers Squibb Company, Princeton, NJ (US);
Abstract
The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that may stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.